Celldex Total Liab vs Short Term Investments Analysis

CLDX Stock

USD 37.42 0.42 1.14%

Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Total Liab and its Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Total Liab vs Short Term Investments

Total Liab vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Total Liab account and Short Term Investments. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Celldex Therapeutics' Total Liab and Short Term Investments is -0.05. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Total Liab and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Celldex Therapeutics are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Total Liab i.e., Celldex Therapeutics' Total Liab and Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Short Term Investments

Short Term Investments is an item under the current assets section of Celldex Therapeutics balance sheet. It contains any investments Celldex Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Celldex Therapeutics can easily liquidate in the marketplace.

Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.

	2023	2024 (projected)
Extraordinary Items	17.2M	15.3M
Reconciled Depreciation	2.9M	3.1M

Extraordinary Items Reconciled Depreciation

Celldex Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Currrent Assets Other	Inventory	Accounts Payable	Short Long Term Debt Total	Short Term Debt	Common Stock Total Equity	Common Stock	Intangible Assets
Total Assets		0.67	0.79	0.98	0.28	-0.43	-0.67	0.39	0.21	0.94	0.69	0.12	0.42	0.8	0.33	0.83	0.94	0.49	-0.04	0.14	0.73	-0.27	-0.15	0.39	0.39	0.19
Other Current Liab	0.67		0.7	0.6	0.36	-0.31	-0.38	0.27	0.37	0.54	0.38	0.37	0.33	0.47	0.49	0.54	0.54	0.59	0.04	0.03	0.67	-0.05	-0.02	0.34	0.34	0.51
Total Current Liabilities	0.79	0.7		0.7	0.71	-0.29	-0.38	0.28	0.51	0.62	0.27	0.44	0.33	0.49	0.66	0.51	0.62	0.49	0.35	0.06	0.61	0.06	0.29	0.67	0.67	0.47
Total Stockholder Equity	0.98	0.6	0.7		0.16	-0.43	-0.69	0.4	0.05	0.98	0.76	-0.05	0.4	0.82	0.16	0.87	0.98	0.47	-0.17	0.2	0.75	-0.32	-0.26	0.27	0.27	0.03
Property Plant And Equipment Net	0.28	0.36	0.71	0.16		-0.38	0.23	0.41	0.63	0.06	-0.42	0.6	0.05	-0.15	0.73	-0.1	0.06	0.01	0.64	-0.08	0.11	0.37	0.68	0.75	0.75	0.53
Net Debt	-0.43	-0.31	-0.29	-0.43	-0.38		-0.07	-0.99	-0.05	-0.42	0.06	0.02	0.02	-0.05	-0.09	-0.05	-0.42	0.04	0.05	-0.07	-0.23	0.3	0.09	-0.39	-0.39	0.03
Retained Earnings	-0.67	-0.38	-0.38	-0.69	0.23	-0.07		0.11	-0.05	-0.65	-0.87	0.04	-0.55	-0.98	-0.06	-0.75	-0.66	-0.64	0.21	0.22	-0.56	0.33	0.35	0.22	0.22	-0.08
Cash	0.39	0.27	0.28	0.4	0.41	-0.99	0.11		0.05	0.39	-0.1	-0.02	-0.04	0.01	0.09	0.01	0.38	-0.08	-0.05	0.09	0.18	-0.21	-0.02	0.39	0.39	-0.05
Non Current Assets Total	0.21	0.37	0.51	0.05	0.63	-0.05	-0.05	0.05		-0.14	-0.26	0.96	0.15	0.04	0.95	-0.1	-0.13	0.11	0.68	-0.25	-0.05	0.23	0.58	0.67	0.67	0.87
Cash And Short Term Investments	0.94	0.54	0.62	0.98	0.06	-0.42	-0.65	0.39	-0.14		0.78	-0.22	0.36	0.79	0.0	0.87	1.0	0.44	-0.28	0.24	0.74	-0.36	-0.36	0.16	0.16	-0.12
Common Stock Shares Outstanding	0.69	0.38	0.27	0.76	-0.42	0.06	-0.87	-0.1	-0.26	0.78		-0.33	0.46	0.9	-0.22	0.9	0.79	0.52	-0.52	0.14	0.66	-0.31	-0.53	-0.28	-0.28	-0.19
Non Current Liabilities Total	0.12	0.37	0.44	-0.05	0.6	0.02	0.04	-0.02	0.96	-0.22	-0.33		0.14	-0.06	0.96	-0.18	-0.22	0.05	0.7	-0.34	-0.16	0.23	0.54	0.62	0.61	0.95
Other Current Assets	0.42	0.33	0.33	0.4	0.05	0.02	-0.55	-0.04	0.15	0.36	0.46	0.14		0.52	0.24	0.52	0.38	0.14	0.14	-0.24	0.54	-0.19	-0.17	0.04	0.04	0.21
Other Stockholder Equity	0.8	0.47	0.49	0.82	-0.15	-0.05	-0.98	0.01	0.04	0.79	0.9	-0.06	0.52		0.08	0.83	0.79	0.66	-0.22	-0.11	0.66	-0.34	-0.35	-0.11	-0.11	0.06
Total Liab	0.33	0.49	0.66	0.16	0.73	-0.09	-0.06	0.09	0.95	0.0	-0.22	0.96	0.24	0.08		-0.01	0.0	0.14	0.7	-0.27	0.04	0.21	0.54	0.72	0.72	0.91
Property Plant And Equipment Gross	0.83	0.54	0.51	0.87	-0.1	-0.05	-0.75	0.01	-0.1	0.87	0.9	-0.18	0.52	0.83	-0.01		0.88	0.42	-0.35	0.31	0.77	-0.16	-0.31	-0.01	0.0	-0.06
Total Current Assets	0.94	0.54	0.62	0.98	0.06	-0.42	-0.66	0.38	-0.13	1.0	0.79	-0.22	0.38	0.79	0.0	0.88		0.45	-0.28	0.23	0.75	-0.36	-0.36	0.16	0.16	-0.11
Net Receivables	0.49	0.59	0.49	0.47	0.01	0.04	-0.64	-0.08	0.11	0.44	0.52	0.05	0.14	0.66	0.14	0.42	0.45		0.06	-0.23	0.53	-0.21	-0.07	-0.05	-0.04	0.13
Non Currrent Assets Other	-0.04	0.04	0.35	-0.17	0.64	0.05	0.21	-0.05	0.68	-0.28	-0.52	0.7	0.14	-0.22	0.7	-0.35	-0.28	0.06		-0.47	-0.15	0.06	0.57	0.55	0.55	0.59
Inventory	0.14	0.03	0.06	0.2	-0.08	-0.07	0.22	0.09	-0.25	0.24	0.14	-0.34	-0.24	-0.11	-0.27	0.31	0.23	-0.23	-0.47		0.3	0.1	-0.09	0.26	0.27	-0.43
Accounts Payable	0.73	0.67	0.61	0.75	0.11	-0.23	-0.56	0.18	-0.05	0.74	0.66	-0.16	0.54	0.66	0.04	0.77	0.75	0.53	-0.15	0.3		-0.32	-0.32	0.19	0.2	-0.06
Short Long Term Debt Total	-0.27	-0.05	0.06	-0.32	0.37	0.3	0.33	-0.21	0.23	-0.36	-0.31	0.23	-0.19	-0.34	0.21	-0.16	-0.36	-0.21	0.06	0.1	-0.32		0.79	0.07	0.06	0.19
Short Term Debt	-0.15	-0.02	0.29	-0.26	0.68	0.09	0.35	-0.02	0.58	-0.36	-0.53	0.54	-0.17	-0.35	0.54	-0.31	-0.36	-0.07	0.57	-0.09	-0.32	0.79		0.45	0.44	0.39
Common Stock Total Equity	0.39	0.34	0.67	0.27	0.75	-0.39	0.22	0.39	0.67	0.16	-0.28	0.62	0.04	-0.11	0.72	-0.01	0.16	-0.05	0.55	0.26	0.19	0.07	0.45		1.0	0.45
Common Stock	0.39	0.34	0.67	0.27	0.75	-0.39	0.22	0.39	0.67	0.16	-0.28	0.61	0.04	-0.11	0.72	0.0	0.16	-0.04	0.55	0.27	0.2	0.06	0.44	1.0		0.45
Intangible Assets	0.19	0.51	0.47	0.03	0.53	0.03	-0.08	-0.05	0.87	-0.12	-0.19	0.95	0.21	0.06	0.91	-0.06	-0.11	0.13	0.59	-0.43	-0.06	0.19	0.39	0.45	0.45

Click cells to compare fundamentals

Celldex Therapeutics Account Relationship Matchups

Celldex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	122.9M	235.8M	444.7M	352.7M	465.6M	488.9M
Other Current Liab	2.0M	3.4M	1.6M	13.8M	26.0M	27.3M
Total Current Liabilities	11.6M	14.2M	16.5M	18.6M	31.1M	32.7M
Total Stockholder Equity	94.0M	209.4M	419.5M	326.2M	429.2M	450.6M
Property Plant And Equipment Net	4.0M	3.8M	3.6M	3.7M	6.6M	5.7M
Net Debt	(7.6M)	(40.4M)	(36.1M)	(25.4M)	(32.3M)	(33.9M)
Retained Earnings	(1.0B)	(1.1B)	(1.1B)	(1.3B)	(1.4B)	(1.3B)
Cash	11.2M	43.8M	39.1M	29.4M	34.8M	31.5M
Non Current Assets Total	56.2M	38.0M	33.8M	35.0M	33.9M	31.0M
Cash And Short Term Investments	64.4M	194.4M	408.3M	305.0M	421.7M	442.8M
Common Stock Shares Outstanding	14.5M	29.6M	42.9M	46.9M	48.4M	50.9M
Liabilities And Stockholders Equity	122.9M	235.8M	444.7M	352.7M	465.6M	488.9M
Non Current Liabilities Total	17.3M	12.3M	8.7M	7.9M	5.3M	5.1M
Other Current Assets	2.3M	3.4M	2.6M	12.7M	5.5M	2.9M
Other Stockholder Equity	1.1B	1.3B	1.6B	1.6B	1.8B	1.9B
Total Liab	28.9M	26.5M	25.2M	26.5M	36.5M	25.7M
Property Plant And Equipment Gross	7.5M	7.3M	27.6M	29.4M	29.0M	30.5M
Total Current Assets	66.7M	197.8M	410.8M	317.7M	431.7M	453.3M
Accumulated Other Comprehensive Income	2.6M	2.6M	1.9M	1.3M	3.3M	3.5M
Net Receivables	1.0M	1.8M	172K	347K	4.5M	4.8M
Inventory	(1.0M)	(1.8M)	(172K)	(347K)	1.0	0.95
Accounts Payable	1.2M	1.0M	1.2M	3.3M	3.5M	3.7M
Short Long Term Debt Total	3.7M	3.5M	3.0M	4.0M	2.5M	4.6M
Short Term Debt	1.9M	1.3M	1.7M	1.4M	1.6M	2.6M
Common Stock Total Equity	12K	17K	40K	47K	54.1K	65.1K
Common Stock	12K	17K	40K	47K	56K	64.5K
Intangible Assets	52.2M	34.2M	30.3M	31.3M	27.2M	34.2M
Current Deferred Revenue	2.5M	6.5M	8.5M	12M	10.8M	10.3M
Other Liab	15.6M	10.1M	7.4M	5.3M	6.1M	5.8M
Property Plant Equipment	4.0M	7.3M	6.5M	7.7M	7.0M	7.2M
Short Term Investments	53.2M	150.6M	369.1M	275.5M	386.9M	406.2M
Net Tangible Assets	45.3M	178.7M	392.3M	299.0M	343.9M	361.1M
Retained Earnings Total Equity	(962.4M)	(1.0B)	(1.1B)	(1.1B)	(1.0B)	(1.1B)
Capital Surpluse	1.1B	1.1B	1.3B	1.6B	1.8B	1.0B
Non Current Liabilities Other	17.3M	10.1M	7.4M	5.3M	4.4M	4.2M

Pair Trading with Celldex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Celldex Stock

0.64

VKTX

Viking Therapeutics

Pair Corr

The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.

The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Celldex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Celldex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Celldex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Celldex Therapeutics Stock:

How To Invest In Celldex

Details

Is Celldex Stock a good investment?

Details

What is Celldex Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Celldex Stock analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

	CEOs Directory Screen CEOs from public companies around the world
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.92)

Revenue Per Share

0.142

Quarterly Revenue Growth

1.561

Return On Assets

(0.22)

Return On Equity

(0.37)

The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Celldex Total Liab vs Short Term Investments Analysis

Total Liab vs Short Term Investments

Total Liab vs Short Term Investments Correlation Analysis

Correlation Coefficient

Total Liab

Short Term Investments

Celldex Therapeutics fundamental ratios Correlations

Celldex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Celldex Therapeutics fundamental ratios Accounts

Pair Trading with Celldex Therapeutics

Moving together with Celldex Stock

Complementary Tools for Celldex Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Stockholder Equity
Non Current Liabilities Total	+ 0.96	Non Current Assets Total

Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.87	Retained Earnings
Property Plant And Equipment Gross	- 0.75	Retained Earnings
Retained Earnings	- 0.69	Total Stockholder Equity
Retained Earnings	- 0.67	Total Assets